Annual Report

Overview

The report describes a year of strong consolidated growth, including 17.5% revenue growth and consolidated net revenue of 34,669,172,052 Taka. It highlights the acquisition and integration of Synovia Pharma and the launch of generic COVID-19 treatments including Paxlovid. The report also details operation of a new PLC-based membrane bioreactor wastewater-treatment facility and continued environmental and occupational-safety initiatives.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021-2022
Period: 1 July 2021 – 30 June 2022
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services